Rx Sight, Inc. RXST
We take great care to ensure that the data presented and summarized in this overview for RxSight, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RXST
View all-
Ra Capital Management, L.P. Boston, MA3.92MShares$177 Million2.7% of portfolio
-
Black Rock Inc. New York, NY2.4MShares$108 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.29MShares$103 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC1.75MShares$78.8 Million0.01% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI1.17MShares$52.8 Million0.09% of portfolio
-
Lord, Abbett & Co. LLC Jersey City, NJ1.05MShares$47.4 Million0.17% of portfolio
-
Invesco Ltd. Atlanta, GA988KShares$44.6 Million0.01% of portfolio
-
State Street Corp Boston, MA818KShares$36.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA817KShares$36.9 Million0.0% of portfolio
-
Divisadero Street Capital Management, LP Miami, FL774KShares$34.9 Million5.16% of portfolio
Latest Institutional Activity in RXST
Top Purchases
Top Sells
About RXST
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Insider Transactions at RXST
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 18
2024
|
Ilya Goldshleger |
SELL
Open market or private sale
|
Direct |
3,100
-3.42%
|
$139,500
$45.04 P/Share
|
|
Nov 18
2024
|
Ilya Goldshleger |
BUY
Exercise of conversion of derivative security
|
Direct |
3,100
+6.4%
|
$46,500
$15.08 P/Share
|
|
Nov 15
2024
|
Ilya Goldshleger |
SELL
Open market or private sale
|
Direct |
4,875
-10.35%
|
$224,250
$46.0 P/Share
|
|
Nov 15
2024
|
Ilya Goldshleger |
BUY
Exercise of conversion of derivative security
|
Direct |
4,875
+9.38%
|
$73,125
$15.08 P/Share
|
|
Nov 13
2024
|
Jesse Anderson Corley |
BUY
Open market or private purchase
|
Direct |
5,795
+7.13%
|
$254,980
$44.74 P/Share
|
|
Nov 13
2024
|
Jesse Anderson Corley |
BUY
Open market or private purchase
|
Indirect |
5,570
+1.16%
|
$250,650
$45.0 P/Share
|
|
Nov 12
2024
|
Ilya Goldshleger |
SELL
Open market or private sale
|
Direct |
1,330
-3.05%
|
$61,180
$46.13 P/Share
|
|
Nov 12
2024
|
Ilya Goldshleger |
BUY
Exercise of conversion of derivative security
|
Direct |
1,330
+2.96%
|
$19,950
$15.08 P/Share
|
|
Nov 12
2024
|
Jesse Anderson Corley |
BUY
Open market or private purchase
|
Indirect |
11,111
+2.32%
|
$499,995
$45.37 P/Share
|
|
Nov 07
2024
|
Ilya Goldshleger |
SELL
Open market or private sale
|
Direct |
3,100
-3.43%
|
$170,500
$55.24 P/Share
|
|
Nov 07
2024
|
Ilya Goldshleger |
BUY
Exercise of conversion of derivative security
|
Direct |
3,100
+6.4%
|
$46,500
$15.08 P/Share
|
|
Nov 04
2024
|
Ilya Goldshleger |
SELL
Open market or private sale
|
Direct |
3,100
-3.44%
|
$158,100
$51.36 P/Share
|
|
Nov 04
2024
|
Ilya Goldshleger |
BUY
Exercise of conversion of derivative security
|
Direct |
3,100
+6.4%
|
$46,500
$15.08 P/Share
|
|
Oct 30
2024
|
Ilya Goldshleger |
SELL
Open market or private sale
|
Direct |
3,105
-6.85%
|
$158,355
$51.91 P/Share
|
|
Oct 30
2024
|
Ilya Goldshleger |
BUY
Exercise of conversion of derivative security
|
Direct |
3,105
+6.41%
|
$46,575
$15.08 P/Share
|
|
Oct 28
2024
|
Ilya Goldshleger |
SELL
Open market or private sale
|
Direct |
3,100
-6.84%
|
$155,000
$50.64 P/Share
|
|
Oct 28
2024
|
Ilya Goldshleger |
BUY
Exercise of conversion of derivative security
|
Direct |
3,100
+6.4%
|
$46,500
$15.08 P/Share
|
|
Oct 25
2024
|
Ilya Goldshleger |
SELL
Open market or private sale
|
Direct |
3,100
-6.84%
|
$151,900
$49.79 P/Share
|
|
Oct 25
2024
|
Ilya Goldshleger |
BUY
Exercise of conversion of derivative security
|
Direct |
3,100
+6.4%
|
$46,500
$15.08 P/Share
|
|
Oct 22
2024
|
Ilya Goldshleger |
SELL
Open market or private sale
|
Direct |
3,100
-6.84%
|
$151,900
$49.68 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 20.4K shares |
|---|---|
| Other acquisition or disposition | 2.31K shares |
| Open market or private purchase | 35.5K shares |
| Bona fide gift | 54K shares |
| Exercise of conversion of derivative security | 357K shares |
| Bona fide gift | 57K shares |
|---|---|
| Open market or private sale | 1.16M shares |
| Other acquisition or disposition | 445K shares |